TOMI's SteraMist Surge: 3 Consecutive Quarters of Growth, a Novel EPA Label, and a Merger That Could Remake the Balance Sheet

A microcap decontamination specialist is posting triple-digit revenue growth, expanding backlog to $2.6M, and plotting a $10M financing through its Carbonium Core merger — all while the stock has already run +203% in 90 days.

TOMZ · Earnings Call · 2026-08-14

From turnaround to proof: the operating story

TOMI Environmental Solutions' Q2 2026 report is a genuine inflection point. After three consecutive quarters of growth, revenue hit $2.25 million, up 118% year-over-year and 36% sequentially. The company's CFO, Niroshan Srirathan, framed it as evidence of operating leverage: “Our loss from operations improved by 78% to approximately $244,000 compared to an operating loss of approximately $1.13 million in Q2 2025. This approximate $889,000 year-over-year reduction in operating loss demonstrates meaningful operating leverage and puts us within clear striking distance of operating breakeven.” — Niroshan Srirathan, Interim Chief Financial Officer · 2026-08-14 That leverage shows up in the fundamentals: Total Revenue has been on a choppy descent since its 2020 peak, but the current quarter's +118% y/y jump is the strongest single-quarter move in years, and gross margin expanded to 61.7% from 50.3% in Q1, a sequential improvement driven by high-margin consumables. The razor-and-blade model is now visibly working: applicator sales reached $355,000 in Q2, up from just $13,000 a year earlier, and management highlighted this as support service synergies converting into repeat BIT Solution orders. The growth isn't just in the top line. The company's sales backlog has expanded from $1.6M at year-end to $2.6M post-quarter, even as orders are being fulfilled. CFO Srirathan reiterated full-year revenue guidance of at least $12 million, with booked orders and expected completions before year-end exceeding $6.2 million. The hybrid system has become a key product introduction, and EJ Shane noted its flexibility: “The hybrid system, John, is a mix of our mobile fogger and permanent applicators. So the whole strategy behind the last 1.5 years or so has been allowing the customer to decide how and when they want to use the equipment.” — Elissa Shane, Chief Operating Officer · 2026-08-14

Pipeline, regulatory wins, and the Carbonium pivot

The pipeline story is more forward-looking: roughly $35 million in total identified interest, with $8.6M in advanced stages expected to close in 2026. Management highlighted a $1M custom engineered system (CES) that is out for bid, a second $1M project from a multinational health care manufacturer, and a potential order for 8 hybrid systems from a Canadian partner. On the regulatory front, TOMI received a new EPA label for AgriMist, its fourth EPA registration, which authorizes direct application of iHP to indoor grown plants and fruits, including avocados, up to and including the day of harvest. This is a meaningful expansion into food safety and agriculture. The bigger strategic pivot is the proposed merger with Carbonium Core, a nuclear graphite and lithium developer. Management attaches a combined valuation of $180 million (Carbonium $120M, TOMI $60M). CEO Halden Shane framed the deal against a backdrop of U.S. critical mineral policy, and the company has already booked ~$300,000 of advisory and legal costs tied to the deal. A $10 million minimum concurrent financing condition remains before closing, and a recent round of note conversions reduced near-term overhang:

I am also very happy to announce the improved financial performance this quarter and the recent agreement with certain noteholders to convert approximately $2.3 million of their outstanding convertible notes into shares. We believe we will be able to regain compliance with stockholder equity requirements under NASDAQ's continuing listing rules subject to final review and approval by the NASDAQ hearing panel.
Halden Shane, Chief Executive Officer and Chairman · 2026-08-14

The balance sheet is still thin: cash and equivalents at quarter-end were just $322,000, and working capital was $1.82 million. But the company now has ~$18.1 million of remaining contractual capacity under its ELOC, and the post-quarter note conversion and omnibus amendment (lowering the conversion price from $3.75 to $1.50) are steps to clean up the equity base.

What has actually changed — and what hasn't

The earnings call text this quarter is striking for how much fresh information it contains relative to prior calls. In the May 2026 call, the conversation was mostly about the early Carbonium diligence and whether discounts would persist. Here, the tone has shifted to execution: "“Our second quarter results demonstrated a revenue increase of 118% year-over-year and 36% sequentially from the first quarter of 2026.” — Halden Shane, Chief Executive Officer and Chairman · 2026-08-14" That quote is from CEO Halden Shane and marks a clear change in narrative. But not everything has changed. In the May call, management said they expected to reach profitability within the year; now they more specifically target breakeven in Q4 2026. Prior transcript evidence shows the same recurring themes: the Carbonium merger was described as "early stages" and "diligence" in May 2026 (component 5181234985537534235), and in the third-quarter 2025 call (2025-11-14), management was already talking about the "razor/razor-blade" model and FDA progress (component 2327866804334741251). So the pieces have been building, but the concrete numbers in this quarter — the 118% growth, the applicator adoption, the backlog expansion — finally substantiate the story. Investors should still be careful about the stock's recent run. TOMZ has risen +203.5% in the last 90 days, peaking at $1.93 early in August, and remains about 8.8% below that high. Over a longer window, the stock is still down about 81% from its 2010 peak, and the market cap is only ~$16 million. The company's fundamentals are improving, but the stock is trading on a multi-quarter narrative, not just a two-quarter rebound. The biggest swing factor is the Carbonium merger closing, which hinges on raising $10 million and NASDAQ approval. If that financing fails, the small-cap balance sheet could be tested again.